FREDERICK, Md. — Akonni Biosystems, which develops, manufactures and intends to market advanced molecular diagnostics systems, recently announced receipt of a $3 million, three-year Phase II Small Business Innovation Research contract from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Akonni received the Phase I contract in August 2016. During that, Akonni completed each milestone set forth by the NIH, resulting in a device that can process high-volume sputum samples for Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
Phase II product development will focus on meeting the requirements of a low-resource setting, including industrial design elements such as dust-protection, battery power and user interface. It will also include a plan to transfer the device to commercial production. The system will be validated using a real-time test for tuberculosis to determine analytical and clinical sensitivity of the method as compared to a standard laboratory method.